In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celldex Therapeutics Inc.

www.celldextherapeutics.com

Latest From Celldex Therapeutics Inc.

Finance Watch: 14 Biopharma IPOs In One Remarkable Month

Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.

Financing Business Strategies

Gender Diversity In Pharma: Caught Between Desire And Reality

Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete. 

Leadership Strategy

Lupin’s Karkaria Addresses Biosimilars Pushback

Lupin's biotech president notes push-back by innovator firms against biosimilars in the US parallels that witnessed when small molecule generic competition first emerged, but remains confident that biosimilars will gain traction. The executive also sees little need for separate interchangeability studies.

Biosimilars Strategy

Lupin’s Karkaria On Biosimilars Pushback And Interchangeability

Lupin's biotech president notes push-back by innovator firms against biosimilars in the US parallels that witnessed when small molecule generic competition first emerged, but remains confident that biosimilars will gain traction. The executive also sees little need for separate interchangeability studies.

Commercial Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Virus Research Institute Inc.
  • T Cell Sciences
  • Avant Immunotherapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Celldex Therapeutics Inc.
  • Senior Management
  • Anthony S Marucci, Pres. & CEO
    Sam Martin, SVP, CFO
    Tibor Keler, PhD, EVP, CSO
    Ronald A Pepin, PhD, SVP, CBO
    Richard Wright, Chief Commercial Officer
    Diane C Young, MD, SVP, CMO
  • Contact Info
  • Celldex Therapeutics Inc.
    Phone: (908) 454-7120
    53 Frontage Rd.
    Ste. 220
    Hampton, NJ 08827
    USA
UsernamePublicRestriction

Register